Visby Medical

Visby Medical

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Visby Medical is a commercial-stage diagnostics company pioneering rapid, portable PCR testing for consumer use. Its core innovation is a handheld, single-use PCR device that enables lab-quality molecular diagnostics outside traditional clinical settings, starting with an FDA-authorized at-home STI test. The company operates a direct-to-consumer e-commerce model, selling test kits online and providing integrated telehealth services for treatment. Visby aims to disrupt the diagnostics market by making complex testing simple, fast, and private, addressing significant gaps in sexual health screening.

Infectious DiseaseSexual Health

Technology Platform

Proprietary, handheld, single-use PCR device that performs full molecular diagnostic testing (sample prep, amplification, detection) in about 30 minutes, enabling lab-quality testing at home or at the point-of-care.

Opportunities

The high and growing incidence of STIs, combined with significant barriers to traditional clinic-based testing (stigma, access, wait times), creates a large addressable market for convenient, private, and rapid at-home diagnostics.
The adaptable PCR platform also presents opportunities to expand into other infectious disease areas and professional point-of-care settings.

Risk Factors

Key risks include intense competition in the digital health and at-home testing space, the high cost of customer acquisition for a direct-to-consumer model, ongoing regulatory requirements for maintaining and expanding FDA authorizations, and the challenge of achieving profitability while scaling.

Competitive Landscape

Visby competes with other at-home STI test providers like Everlywell and LetsGetChecked (which use mail-in lab services), as well as traditional clinic and lab networks. Its primary differentiation is the speed (30-minute) and platform (true PCR at home). It also faces future competition from other companies developing point-of-care molecular devices for professional use.